Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is a cornerstone in the pharmacological treatment of major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Its widespread efficacy and relatively favorable side-effect profile have cemented its position as one of the most commonly prescribed antidepressants globally. For pharmaceutical manufacturers, distributors, and healthcare providers, a nuanced understanding of the global Escitalopram buyers’ landscape is paramount for efficient procurement, strategic market entry, and ensuring patient access to this vital medication. This article delves into the intricate ecosystem of the global Escitalopram market, shedding light on the key entities driving its demand, the critical factors influencing purchasing decisions, and the prevailing…